Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Immunogen Inc (IMGN)

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,010,866
  • Shares Outstanding, K 220,713
  • Annual Sales, $ 69,860 K
  • Annual Income, $ -139,300 K
  • 60-Month Beta 0.90
  • Price/Sales 14.85
  • Price/Cash Flow N/A
  • Price/Book 4.15
Trade IMGN with:

Options Overview Details

View History
  • Implied Volatility 133.72% ( +38.05%)
  • Historical Volatility 65.65%
  • IV Percentile 91%
  • IV Rank 45.88%
  • IV High 222.33% on 05/11/22
  • IV Low 58.61% on 05/27/22
  • Put/Call Vol Ratio 1.38
  • Today's Volume 993
  • Volume Avg (30-Day) 1,182
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 21,637
  • Open Int (30-Day) 25,790

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.26
  • Number of Estimates 8
  • High Estimate -0.23
  • Low Estimate -0.30
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -44.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.43 +3.39%
on 09/23/22
6.63 -30.92%
on 08/24/22
-1.54 (-25.16%)
since 08/23/22
3-Month
4.22 +8.53%
on 06/29/22
6.63 -30.92%
on 08/24/22
+0.21 (+4.81%)
since 06/23/22
52-Week
3.10 +47.98%
on 06/14/22
7.77 -41.06%
on 12/01/21
-1.52 (-24.92%)
since 09/23/21

Most Recent Stories

More News
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will participate...

IMGN : 4.58 (-2.55%)
ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced findings from an analysis of patient-reported outcomes (PROs)...

IMGN : 4.58 (-2.55%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on August 31, 2022, the compensation committee of the...

IMGN : 4.58 (-2.55%)
Immunogen (IMGN) Provides Preliminary Data on Rare Blood Cancer Candidate

Immunogen (IMGN) announces preliminary data on its CADENZA study evaluating pivekimab in blastic plasmacytoid dendritic cell neoplasm.

JAZZ : 127.67 (-2.23%)
IMGN : 4.58 (-2.55%)
CPRX : 11.87 (-2.70%)
AERI : 15.12 (-0.13%)
Esperion Therapeutics (ESPR) Up 29.3% Since Last Earnings Report: Can It Continue?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ESPR : 6.70 (-3.74%)
IMGN : 4.58 (-2.55%)
ImmunoGen Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today provided an update on the pivotal Phase 2 CADENZA study of pivekimab...

IMGN : 4.58 (-2.55%)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on July 29, 2022, the compensation committee of the...

IMGN : 4.58 (-2.55%)
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.

RHHBY : 39.6000 (-1.10%)
IMGN : 4.58 (-2.55%)
IONS : 43.23 (-3.87%)
VRCA : 2.88 (-5.88%)
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript

IMGN earnings call for the period ending June 30, 2022.

IMGN : 4.58 (-2.55%)
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 4.58 (-2.55%)
ADXN : 0.7953 (+1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

ImmunoGen Inc is a development-stage biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate technology. ImmunoGen's ADC technology is used in three development-stage candidates in its own pipeline, Roche's marketed product, Kadcyla...

See More

Key Turning Points

3rd Resistance Point 5.05
2nd Resistance Point 4.89
1st Resistance Point 4.74
Last Price 4.58
1st Support Level 4.43
2nd Support Level 4.27
3rd Support Level 4.12

See More

52-Week High 7.77
Fibonacci 61.8% 5.98
Fibonacci 50% 5.43
Fibonacci 38.2% 4.88
Last Price 4.58
52-Week Low 3.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar